What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD”In the company’s words, NCT05473910 on ClinicalTrials.gov
Other drugs for AML
- SonrotoclaxBeOne Medicines (BeiGene) · Phase 3
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- LisaftoclaxAscentage Pharma Group Inc. · Phase 3
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 1 Jun 2026 | A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026